Connect with us

Industry

Cannabis and IVF: Study reveals consumption may not be associated with compromised effects

The Canadian and Israeli study examined results from over 722 patients who consumed or did not consume cannabis

Published

on

IVF: A person holding a blue and white pregnancy test looks down a positive result of two lines across a screen.

A study from researchers in Canada and Israel have revealed that a history of cannabis use is not associated with compromised effects on IVF.

The study, published in the Journal of Cannabis Use, on the effects of a person’s history of cannabis use found it is not associated with compromised effects on in vitro fertilisation (IVF).

The team of researchers from Canada and Israel studied IVF treatment outcomes of male and female, non-donor patients who were cannabis consumers or not. They focused on the ongoing pregnancy rate as well as oocyte yield, fertilization rate, peak serum estradiol, sperm, and embryo quality.

There were 722 participants involved in the research of which, 68 percent were cannabis users who were mostly defined as light consumers. The study revealed a similar implantation rate at 40.74 percent compared to 41.13 percent. It also highlighted similar rates of ongoing pregnancy at 35.2 percent to 29.1 percent between users and non-users. There were no significant differences between consumers and non-consumers in any of the other areas of focus.

IVF and cannabis use

They stated: “Our study did not show any detrimental impact of current cannabis use on any of the measured IVF outcomes. … All the reproductive outcomes of cannabis users and non-users in our study were comparable. These parameters included measures of ovarian response, sperm quality, the efficiency of fertilisation, early embryonic development, and implantation.”

“In fact, the ongoing pregnancy rate per cycle start trended higher for the group of cannabis users (35.2 percent vs. 29.1 percent). This could partially relate to the female participants in the user group being younger than the non-user counterparts.”

READ MORE  "It's still very taboo": How medical cannabis helps relieve the pain of vulvodynia

The concluded: “They concluded, “The results of this study are in line with the newer studies suggesting that the use of cannabis is not associated with a compromised outcome for couples undergoing IVF.”

Read more: Could cannabis help with alopecia?

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Industry

Rapper Lil’ Kim announces new cannabis brand ‘aphrodisiac’

The New York rapper becomes the latest celebrity to launch their own cannabis collection which is due in 2022.

Published

on

Image: Instagram/lilkimthequeenbee

The singer has announced the launch of her own cannabis brand, Aphrodisiac which is being produced in partnership with Superbad inc.

Lil Kim’s new products will be available across California in 2022, although there is no official launch date announced.

The brand is being produced in collaboration with the innovative cannabis brand, Superbad inc. Superbad was established in 2020 combining cutting edge technology and sleek design for cannabis consumers. They currently have seven acres of indoor grow and a “state-of-the-art facility” employing over 200 people.

Kimberly Denise Jones who goes by her stage name, Lil’ Kim has been working on the brand for two years. She has also partnered with the brand CampNova, which offer vertically integrated marketing and a distribution platform.

The rapper wants the cannabis line to reflect her personal style and says she has personally tested her own products. The collection is tailored to Lil’ Kim’s own preference in genetics and strains.

Lil' Kim: A banner advert for Always Pure Organics

Lil’ Kim collection

There are plans to expand the range to other legal states such as Michigan, New Jersey and New York. Originally from New York, Lil’ Kim hopes to be able to release the collection in her home state.

In an interview with Forbes magazine, she said: “I’ve actually been working on this for about two and a half to three years. This is something that didn’t just come overnight. It’s something I’ve always wanted to do.”

Lil’ Kim is the latest celebrity to enter the cannabis space with her own collection. Earlier this year, Justin Bieber announced he would be releasing a collection of pre-rolls called Peaches with premium brand Palms. The products are currently available in California, Nevada, Massachusetts and Florida.

READ MORE  “We’re the party for cannabis consumers - they just don’t know it yet”

In a press release, he stated: “I’m a fan of Palms and what they are doing by making cannabis approachable and helping to destigmatise it — especially for the many people who find it helpful for their mental health.”

 

Image rights: Lil’ Kim

Continue Reading

Industry

Always Pure Organics: A day in the life with Chikako Yoshida

Regional Director of Asia, Chikako Yoshida, gives us a glimpse of her typical workday and discusses working in cannabis.

Published

on

Always Pure Organics: A man and a woman working on a laptop.

Chikako Yoshida, regional director of Asia for Always Pure Organics shares her experience of working in the cannabis industry.

Always Pure Organics is excited to give you a glimpse behind the curtain once again.

Join us for our latest episode of a Day in the Life, in which regional director of Asia, Chikako Yoshida discusses her experience working for Always Pure Organics and in the cannabis industry.

Always Pure Organics: A woman walking down a white and yellow hallway

In this episode, we follow our Regional Director of Asia, Chikako Yoshida, as she takes us through her typical workday. Having previously worked in counterterrorism for the United Nations, Chikako joined the APO team in May 2020. Chikako has such an interesting story to tell, we’re honoured to have her on the team as she embodies our mission to cultivate cannabis acceptance and accessibility worldwide. 

Chikako Yoshida said: “Upon learning about the power of cannabis and seeing the high potential growth of Always Pure Organics, I decided to change career from preventing illicit drugs to promoting cannabis to help people in need. I feel that by joining APO, I can help fulfil my life’s mission to support children and their families who fight against illness and sickness by providing them with cannabis products.”

Read more: Always Pure Organics achieves COSMO standard

Always Pure Organics: A banner explaining how the collaborative post works

READ MORE  Could cannabis help nurses experiencing physical pain while working?
Continue Reading

Epilepsy

CBGA may be ‘more potent’ than CBD against seizures in Dravet syndrome

Dr Lyndsey Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.

Published

on

Seizure: A row of test tubes containing CBGA oil with a doctors white gloved hand holding one up to the light

Scientists say they have found the ‘Mother of all cannabinoids’ which may help to reduce seizures in Dravet syndrome.

A new study on mice from the University of Sydney found that three acidic cannabinoids found in cannabis reduced seizures in Dravet syndrome, an intractable form of childhood epilepsy.

The three cannabinoids are cannabigerolic acid (CBGA), cannabidivarinic acid (CBDVA), cannabigerovarinic acid (CBGVA). All three but CBGA in particular “may contribute to the effects of cannabis-based products in childhood epilepsy” noted the researchers and were found to potentially have ‘anticonvulsant properties.”

The study marks the first time that three acidic cannabinoids were found to potentially help reduce seizures for Dravet syndrome.

Speaking with Cannabis Health News, the lead author of the study, Dr Lyndsey Anderson, said: “We found that CBGA exhibited both anticonvulsant and pro-convulsant effects. CBGA was more potent than CBD against febrile seizures in a mouse model of Dravet syndrome. We also found that a combination of CBGA and clobazam was more effective than either treatment alone. Additionally, we found that CBGA was anticonvulsant in the maximal electroshock acute seizure model, a model for generalized tonic-clonic seizures.”

She added: “CBGA did, however, present some proconvulsant effects. The frequency of spontaneous seizures in the mouse model of Dravet syndrome was increased with a high dose of CBGA. Also, CBGA was proconvulsant in the 6-Hz acute seizure model, a model of focal, psychomotor seizures.”

Although CBGA shows promise, Dr Anderson also stressed that it needs more research before it can replace CBD. She cautioned that Dravet syndrome patients may still need to proceed with caution.

READ MORE  Cannabis consumption by pregnant women increased during pandemic according to new study

“Artisanal cannabis-based products are believed to reduce seizures in Dravet syndrome patients,” she said. “As these oils contain rare cannabinoids like CBGA, it is possible CBGA then contributes to the anticonvulsant effects of these artisanal cannabis oils. However, there were proconvulsant effects observed with CBGA, suggesting that Dravet syndrome patients may need to proceed with caution. The proconvulsant liability of CBGA would need to be addressed before it replaced CBD as an anticonvulsant.”

What is CBGA?

Sometimes referred to as ‘the mother of all cannabinoids,’ CBGA is the precursor molecule to many different cannabinioids including CBD and THC. It is thought to help some diseases such as colon cancer, metabolic disease and cardiovascular disease. It is a non-intoxicating cannabinoid much like CBD.

Dr Anderson explains that more research is needed to explain how the three cannabinoids work together.

“We don’t know how they work together yet,” she said. “We found that CBGA, CBDVA and CBGVA were all individually anticonvulsant against thermally induced seizures in the mouse model of Dravet syndrome. We did not investigate whether a combination of these three cannabinoids would result in a greater anticonvulsant effect than either cannabinoid alone. Future work will definitely explore this possibility.”  

CBGA future research

This isn’t the end of the research into CBGA for Dravet Syndrome. Dr Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.

 

She said: “Next on the horizon for this research is to explore whether the anticonvulsant properties of CBDVA and CBGVA translate to other seizure types including spontaneous seizures in the mouse model of Dravet syndrome. Additionally, we have extensively interrogated the anticonvulsant potential of individual cannabinoids and identified ten with anticonvulsant properties.”

READ MORE  Parkinson's disease and CBD: New studies may reveal positive effects

 

“We are now interested in investigating what happens when we combine these anticonvulsant properties. It remains an open possibility that greater anticonvulsant effects are achieved when the cannabinoids are administered in combination.”

The study was recently published in the British Journal of Pharmacology (DOI: 10.1111/bph.15661)

Continue Reading

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2021 H&W Media Ltd.